Outlook Therapeutics Strengthens Leadership with Appointment Of Biopharma Executive Bob Jahr As Chief Executive Officer

Outlook Therapeutics, Inc., a biopharmaceutical company dedicated to advancing the standard of care for bevacizumab in the treatment of retinal diseases, has announced the appointment of Bob Jahr as its new Chief Executive Officer. Alongside his new role, Mr. Jahr has also joined the Board of Directors of the company. Lawrence A. Kenyon, who has been serving as both Chief Financial Officer and interim CEO, will continue in his role as CFO and remain on the Board.

Bob Jahr brings over two decades of experience in the biopharmaceutical industry, having led commercial and operational teams across a broad range of therapeutic areas, including rare diseases, oncology, hematology, autoimmunity, neuroscience, cardiovascular, and inflammatory conditions. He has been instrumental in the commercial success and lifecycle management of several billion-dollar assets throughout his career.

Most recently, Mr. Jahr served as Chief Commercial Officer at Sobi North America, where he was responsible for the company’s overall commercial strategy and execution. His role covered marketing, sales, operations, and market access. During his time at Sobi, he led the immunology and hematology franchises and oversaw three global development asset teams involved in preparing for regulatory filings, managing product life cycles, and planning product launches.

Before joining Sobi, Mr. Jahr held senior leadership roles at UCB Pharma SA. As General Manager and Vice President, Head of International Markets, he managed UCB’s portfolio across diverse regions such as China, Japan, Australia, Canada, Brazil, the Middle East, and Latin America. He also served as Vice President and Head of U.S. Payer Value, Pricing, Strategy & Innovation at UCB, where he built strategic teams during a critical phase of portfolio growth and product launches.

Faisal G. Sukhtian, Chairman of the Outlook Therapeutics Board of Directors, stated, “We are very pleased to welcome Bob to the executive leadership team as we continue to execute on our path forward. Bob’s experience, track record and deep understanding of the biopharmaceutical industry will be invaluable as we scale as a commercial entity. With our launch in Europe underway and potential U.S. Food and Drug Administration (FDA) approval in the coming months, we believe this appointment is timely and positions us to drive value for our stakeholders.”

Mr. Jahr also added, “LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) has the potential to truly transform the global retina market and offer a much-needed ophthalmic formulation of bevacizumab for wet AMD. With the commercial launch underway in Europe and potential FDA approval in the U.S. in the near term, I am excited to join the team at such a pivotal time for Outlook Therapeutics. I look forward to adding the depth and breadth of my experience to Outlook Therapeutics and continue building momentum to position it as a leader in the ophthalmology market.”

Earlier in his career, Mr. Jahr held leadership positions in sales, marketing, operations, payer strategy, and market access at Amgen. He holds an MBA as well as a Bachelor of Science degree in Business Administration and Management from the University of Montana. With this leadership transition, Outlook Therapeutics aims to strengthen its commercial capabilities and accelerate its mission to redefine treatment options in the retinal disease space.